pyrazines has been researched along with Amyloidosis in 80 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (8.75) | 29.6817 |
2010's | 72 (90.00) | 24.3611 |
2020's | 1 (1.25) | 2.80 |
Authors | Studies |
---|---|
Garrido, D; Riva, E | 1 |
Adam, Z; Cermáková, Z; Hájek, R; Král, Z; Krejčí, M; Mayer, J; Navrátil, M; Pospíšilová, Y; Pour, L; Sandecká, V; Stork, M; Zahradová, L | 1 |
Adam, Z; Cermáková, Z; Král, Z; Krejčí, M; Pour, L; Sčudla, V | 1 |
Huang, XJ; Lu, J; Wang, H | 1 |
Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S | 1 |
Gibbs, SD; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Pinney, JH; Roussel, M; Sachchithanantham, S; Venner, CP; Wechalekar, AD | 1 |
Abe, D; Amagai, M; Hosokawa, R; Murakami, K; Ohyama, M; Okamoto, S; Yokoyama, K | 1 |
Comenzo, R; Cossor, F; Fallo, S; Kaul, E; Klein, A; Miller, K; Shah, G; Smith, H; Sprague, K | 1 |
Bačovský, J; Látalová, P; Lochman, P; Metelka, R; Minařík, J; Pika, T; Ščudla, V; Vymětal, J; Zapletalová, J | 1 |
Chen, W; Chen, Z; Gong, D; Huang, X; Liu, Z; Wang, Q; Zeng, C; Zhang, H | 1 |
Abar, F; Dibb, J; Dibb, W; Frires, R; Heitner, SB; Kovacsovics, T; Maziarz, RT; Meyers, G; Perez-Avraham, G; Scott, EC; Smith, SD; Stentz, A | 1 |
Abildgaard, N; Godskesen, L; Kjeldsen, J; Krag, A | 1 |
Bridoux, F; Comenzo, RL; Decaux, O; Gillmore, J; Hari, P; Hawkins, PN; Jaccard, A; Lavergne, D; Lazaro, E; Macro, M; Mercie, P; Mohty, D; Morel, P; Pellegrin, JL; Roussel, M; Venner, CP; Wechalekar, AD | 1 |
Foard, D; Gibbs, SD; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Lane, T; Mahmood, S; Pinney, JH; Rannigan, L; Sachchithanantham, S; Venner, CP; Wechalekar, AD; Whelan, CJ | 2 |
Asahina, M; Ikeda, S; Kuwabara, S; Sano, K; Shiojiri, T; Sugiyama, A; Takeda, Y | 1 |
de Waal, TT; Gorter, MH; Tascilar, M | 1 |
Basset, M; Foli, A; Lavatelli, F; Merlini, G; Milani, P; Nuvolone, M; Obici, L; Palladini, G; Perlini, S; Vidus Rosin, M | 1 |
Fujiwara, K; Higo, H; Inomata, T; Kameyama, N; Makimoto, G; Matsushita, M; Rai, K; Sato, K; Shibayama, T; Sunami, K; Watanabe, H | 1 |
Merlini, G; Palladini, G | 1 |
Bladé, J; Cakana, A; Comenzo, RL; Enny, C; Esseltine, DL; Fermand, JP; Hassoun, H; Heffner, L; Hegenbart, U; Kukreti, V; Merlini, G; Palladini, G; Pei, L; Reece, DE; Sanchorawala, V; van de Velde, H; Vescio, RA | 1 |
Choi, JO; Jeon, ES; Kim, HJ; Kim, JS; Kim, K; Kim, SJ; Lee, GY; Lee, JE; Lee, JY; Lee, SY; Lim, SH; Min, JH | 1 |
Gertz, MA | 1 |
Hata, H; Hirata, S; Ide, K; Kawaguchi, T; Kikukawa, Y; Matsuno, N; Mitsuya, H; Miyakawa, T; Nakata, H; Nosaka, K; Okuno, Y; Yonemura, Y; Yuki, H | 1 |
Dispenzieri, A | 1 |
Dimopoulos, MA; Gavriatopoulou, M; Kalapanida, D; Kaldara, E; Kastritis, E; Migkou, M; Ntalianis, A; Pamboucas, C; Psimenou, E; Roussou, M; Tasidou, A; Terpos, E; Toumanidis, ST | 1 |
Benner, A; Bochtler, T; Goldschmidt, H; Granzow, M; Hegenbart, U; Ho, AD; Hose, D; Jauch, A; Kimmich, C; Kunz, C; Schönland, SO; Seckinger, A | 1 |
Gotoh, Y; Ihara, K; Inomata, H; Kato, J; Koyama, R; Miyajima, N; Muramatsu, H; Nagamachi, Y; Nishisato, T; Nozawa, E; Okamoto, T; Yamauchi, N | 1 |
Basset, M; Foli, A; Gillmore, J; Hawkins, P; Lachmann, H; Merlini, G; Milani, P; Palladini, G; Sachchithanantham, S; Wechalekar, AD | 1 |
Bladé, J; Cibeira, MT | 1 |
Dispenzieri, A; Warsame, R | 1 |
Benner, A; Bochtler, T; Hegenbart, U; Kunz, C; Schönland, SO | 1 |
Alonso-Pulpón, L; García-Pavía, P; Gómez-Bueno, M; Jaramillo, N; Krsnik, I; Mingo, S; Oteo, JF; Salas, C; Sayago, I; Segovia, J | 1 |
Dimopoulos, MA; Kastritis, E; Rajkumar, SV | 1 |
Cakana, A; Comenzo, RL; Elsayed, YA; Fermand, JP; Hegenbart, U; Liu, X; Merlini, G; Palladini, G; Reece, DE; Sanchorawala, V; Vescio, RA | 1 |
Bitter, M; Brunvand, MW | 1 |
Mehta, AB; Shah, AD; Watts, AJ; Wechalekar, AD | 1 |
Handa, H; Higeta, D; Hirato, J; Karasawa, M; Koiso, H; Mawatari, M; Murakami, H; Nojima, Y; Osaki, Y; Saito, T; Sekigami, T; Tahara, K; Tsukamoto, N; Uchiumi, H; Yokohama, A | 1 |
Li, J; Su, C; Wang, HH; Zeng, LJ; Zhao, Y | 1 |
Dimopoulos, MA; Gillmore, JD; Hawkins, PN; Kastritis, E; Merlini, G; Palladini, G; Perfetti, V; Wechalekar, AD | 1 |
Chaudhary, R; Ghose, A; Taj, A; Tariq, Z | 1 |
Adam, Z; Germáková, Z; Hájek, R; Kovárová, L; Krejcí, M; Kren, L; Krivanová, A; Mardová, J; Mayer, J; Moulis, M; Nedbálková, M; Pour, L; Stepánková, S; Svobodová, I; Veselý, K; Zahradová, L | 1 |
Drach, J; Lamm, W; Lang, A; Ludwig, H; Müldür, E; Schauer-Stalzer, B; Willenbacher, W; Zielinski, CC; Zojer, N | 1 |
Hao, H; Hasegawa, S; Hirota, S; Lee-Kawabata, M; Masuyama, T; Naito, Y; Ogawa, H; Tamaki, H; Taniguchi, Y | 1 |
Cornell, LD; Fidler, ME; Nasr, SH; Qian, Q; Sethi, S | 1 |
Foli, A; Lavatelli, F; Merlini, G; Milani, P; Obici, L; Palladini, G; Russo, P | 1 |
Farrell, K; Soutar, R; Stobo, DB | 1 |
Abraham, J; Bridoux, F; Delbès, S; Desport, E; Fermand, JP; Jaccard, A; Lacotte-Thierry, L; Moumas, E; Touchard, G | 1 |
Brugnatelli, S; Foli, A; Invernizzi, R; Lavatelli, F; Merlini, G; Milani, P; Nuvolone, M; Obici, L; Palladini, G; Russo, P | 1 |
Bladé, J; Cakana, A; Comenzo, RL; Enny, C; Esseltine, DL; Fermand, JP; Hassoun, H; Heffner, L; Hegenbart, U; Liu, K; Merlini, G; Palladini, G; Reece, DE; Sanchorawala, V; van de Velde, H; Vescio, RA | 1 |
Bahram, S; Béné, MC; Davi, F; Gribben, JG; Herbrecht, R; Jacob, F; Leblond, V; Merle-Béral, H; Nadaud, S; Perrot, A; Pionneau, C; Vallat, L | 1 |
Henderson, RA; McGhee, CN; Patel, D; Pradhan, MA; Vincent, AL | 1 |
Bladé, J; Cakana, A; Comenzo, RL; Dubrey, SW; Elsayed, Y; Enny, C; Fermand, JP; Hassoun, H; Heffner, LT; Hegenbart, U; Liu, X; Merlini, G; Mortimer, S; Palladini, G; Ramaswami, P; Reece, DE; Sanchorawala, V; Van De Velde, H; Vescio, RA | 1 |
Badelita, S; Coriu, D; Crisan, M; Dobrea, C; Dogaru, M; Ostroveanu, D; Talmaci, R | 1 |
Abonour, R; Benson, MD; Kramer, G; Suvannasankha, A | 1 |
Antolino, G; Bianchi, MP; De Biase, L; La Verde, G; Monarca, B; Moscetti, A; Porrini, R; Saltarelli, F | 1 |
Andrea, NT; Quillen, K; Sanchorawala, V; Seldin, DC; Sloan, JM | 1 |
Falk, RH | 1 |
Benjamin, M; Gibbs, S | 1 |
Bridoux, F; Delbes, S; Desport, E; Fermand, JP; Jaccard, A; Pourreau, F; Puyade, M; Sirac, C; Touchard, G | 1 |
Andreesen, R; Grube, M; Hafner, C; Hart, C; Wurm, S | 1 |
Foard, D; Gibbs, SD; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Lane, T; Pinney, JH; Rannigan, L; Venner, CP; Wechalekar, AD; Whelan, CJ | 1 |
Bello, N; Bergsagel, PL; Fonseca, R; Jimenez-Zepeda, VH; Mikhael, JR; Reeder, CB; Schuster, SR; Spong, J; Stewart, AK | 1 |
Domján, G; Gadó, K | 1 |
Dispenzieri, A; Gertz, MA | 1 |
Morgan, G | 1 |
Charliński, G; Jedrzejczak, WW; Wiater, E | 1 |
Cheung, J; Cornell, IS; Yau, AH | 1 |
Bockorny, B; Bockorny, M; Bona, R; Chakravarty, S; Schulman, P | 1 |
Arbeille, B; Croué, A; Ifrah, N; Levaltier, X; Marchand, A; Martin, L | 1 |
Suzuki, K | 1 |
Bello, C; Comenzo, RL; Flombaum, C; Giralt, S; Hassoun, H; Hoover, E; Landau, H; Liu, J; Maurer, M; Riedel, E; Rosenzweig, MA | 1 |
Chari, A; Pri-Chen, H | 1 |
Barley, K; Chari, A; Jagannath, S; Osman, K | 1 |
Giralt, S; Landau, H; Rosenzweig, M | 1 |
Gertz, MA; Hayman, SR; Sher, T | 1 |
Gatt, ME; Palladini, G | 1 |
Merlini, G; Palladini, G; Sitia, R | 1 |
Anagnostopoulos, A; Delibasi, S; Dimopoulos, MA; Kastritis, E; Mellou, S; Migkou, M; Nanas, J; Pamboukas, C; Psimenou, E; Roussou, M; Tassidou, A; Terpos, E; Toumanidis, S; Xilouri, I | 1 |
Gillmore, JD; Hawkins, PN; Lachmann, HJ; Offer, M; Wechalekar, AD | 1 |
12 review(s) available for pyrazines and Amyloidosis
Article | Year |
---|---|
[Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
Topics: Amyloidosis; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Humans; Immunoglobulin Light-chain Amyloidosis; Immunosuppressive Agents; Lenalidomide; Pyrazines; Thalidomide | 2013 |
Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
Topics: Age Factors; Amyloidosis; Antineoplastic Agents; Biomarkers; Bone Marrow; Boronic Acids; Bortezomib; Creatinine; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light Chains; Melphalan; Pyrazines; Stem Cell Transplantation; Subcutaneous Fat; Survival Analysis; Troponin T | 2014 |
Treatment of plasma cell dyscrasias with lenalidomide.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Pyrazines; Renal Insufficiency; Thalidomide; Thromboembolism; Waldenstrom Macroglobulinemia | 2008 |
[Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Pyrazines; Thalidomide | 2010 |
[Current treatment of AL amyloidosis].
Topics: Amyloid; Amyloidosis; Biomarkers; Boronic Acids; Bortezomib; Cardiomyopathies; Consensus Development Conferences as Topic; Dexamethasone; Drug Therapy, Combination; Heart Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Failure, Chronic; Kidney Transplantation; Lenalidomide; Melphalan; Natriuretic Peptide, Brain; Paraproteinemias; Paraproteins; Peptide Fragments; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Thalidomide | 2011 |
[Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
Topics: Amyloidosis; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Heart Transplantation; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Light Chains; Kidney; Kidney Diseases; Kidney Transplantation; Melphalan; Paraproteinemias; Plasma Exchange; Pyrazines | 2012 |
[AL amyloidosis].
Topics: Algorithms; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Heart Failure; Humans; Lenalidomide; Melphalan; Myocardium; Palliative Care; Patient Selection; Prognosis; Pyrazines; Quality of Life; Risk Assessment; Risk Factors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2012 |
Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Prognosis; Pyrazines; Thalidomide | 2012 |
Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature.
Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Failure; Humans; Middle Aged; Multiple Myeloma; Myocarditis; Proteasome Inhibitors; Pyrazines | 2012 |
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.
Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Kidney; Lenalidomide; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Renal Insufficiency; Thalidomide | 2012 |
Light-chain amyloidosis: SCT, novel agents and beyond.
Topics: Amyloidosis; Animals; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Immunologic Factors; Immunosuppressive Agents; Immunotherapy; Lenalidomide; Melphalan; Pyrazines; Survival Analysis; Thalidomide | 2013 |
Light chain amyloidosis 2012: a new era.
Topics: Alkylating Agents; Amyloid; Amyloidosis; Biomarkers; Boronic Acids; Bortezomib; Cardiomyopathies; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Forecasting; Humans; Immunoglobulin Light Chains; Immunologic Factors; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Pyrazines; Risk; Severity of Illness Index; Stem Cell Transplantation; Troponin C; Troponin T | 2013 |
8 trial(s) available for pyrazines and Amyloidosis
Article | Year |
---|---|
Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.
Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kidney Diseases; Male; Middle Aged; Prospective Studies; Pyrazines; Survival Rate; Transplantation, Autologous | 2014 |
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Pyrazines; Recurrence; Survival Analysis | 2014 |
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.
Topics: Adult; Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pyrazines; Treatment Outcome | 2009 |
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Protease Inhibitors; Pyrazines; Recurrence | 2011 |
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Heart Diseases; Humans; Kidney Diseases; Liver Diseases; Male; Maximum Tolerated Dose; Middle Aged; Paraproteinemias; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Treatment Outcome | 2011 |
Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Pilot Projects; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2011 |
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.
Topics: Adult; Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Melphalan; Middle Aged; Pyrazines; Stem Cell Transplantation | 2013 |
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pyrazines; Survival Rate; Treatment Outcome | 2007 |
60 other study(ies) available for pyrazines and Amyloidosis
Article | Year |
---|---|
Herpesviral encephalitis associated with bortezomib use in a patient with multiple myeloma and associated light-chain amyloidosis.
Topics: Acyclovir; Amyloidosis; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Dexamethasone; Encephalitis, Herpes Simplex; Herpesvirus 3, Human; Humans; Middle Aged; Multiple Myeloma; Pyrazines | 2022 |
[Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Male; Multiple Myeloma; Pyrazines | 2012 |
[Curative effect observation of patients with primary systemic amyloidosis treated by the combination of bortezomib with dexamethasone and cyclophosphamide].
Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Pyrazines; Retrospective Studies; Treatment Outcome | 2013 |
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Diseases; Boronic Acids; Bortezomib; Carpal Tunnel Syndrome; Dexamethasone; Disease Progression; Doxorubicin; Duodenal Diseases; Female; Femur Head; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Jejunal Diseases; Lenalidomide; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Thalidomide; Vincristine | 2013 |
Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis.
Topics: Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Immunoglobulin D; Male; Middle Aged; Pyrazines; Thalidomide; Treatment Outcome; Vincristine | 2013 |
Improvement of mucocutaneous involvement of immunoglobulin light chain amyloidosis after chemotherapy and hematopoietic stem cell transplantation for multiple myeloma.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Male; Multiple Myeloma; Pyrazines | 2013 |
Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Topics: Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diarrhea; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thrombocytopenia | 2013 |
[Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement].
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Heart Neoplasms; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Melphalan; Middle Aged; Pyrazines; Remission Induction; Thalidomide; Treatment Outcome | 2013 |
Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Topics: Adult; Aged; Amyloidogenic Proteins; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Diseases; Lenalidomide; Male; Melphalan; Middle Aged; Myeloablative Agonists; Proteasome Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
A rare cause of severe hepatomegaly with an improving outcome.
Topics: Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Hepatomegaly; Humans; Male; Multiple Myeloma; Pyrazines | 2014 |
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Protein Aggregates; Pyrazines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2014 |
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Agents; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Paraproteinemias; Pyrazines; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Isolated autonomic failure without evident somatic polyneuropathy in AL amyloidosis.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Neural Conduction; Pure Autonomic Failure; Pyrazines; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2014 |
[Gastrointestinal amyloidosis in a patient with multiple myeloma].
Topics: Abdominal Pain; Amyloidosis; Biopsy; Boronic Acids; Bortezomib; Colon, Sigmoid; Dexamethasone; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2014 |
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Dexamethasone; Humans; Immunoglobulin Light Chains; Melphalan; Middle Aged; Pyrazines; Treatment Outcome | 2014 |
Diffuse parenchymal pulmonary amyloidosis showing an objective response to bortezomib-based chemotherapy.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Boronic Acids; Bortezomib; Female; Humans; Lung Diseases; Multiple Myeloma; Pyrazines; Radiography; Treatment Outcome | 2014 |
Treating advanced cardiac damage in light chain amyloidosis: still an unmet need.
Topics: Amyloidosis; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Pyrazines | 2014 |
Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Prednisolone; Pyrazines; Retrospective Studies | 2014 |
Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Japan; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Pyrazines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Still no certainty about the role of upfront bortezomib among patients with AL amyloidosis.
Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Pyrazines; Treatment Outcome | 2014 |
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Prospective Studies; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; In Situ Hybridization, Fluorescence; Male; Middle Aged; Prognosis; Pyrazines; Retrospective Studies; Translocation, Genetic; Treatment Outcome | 2015 |
[Improvement of hepatomegaly after treatment with autologous hematopoietic stem cell transplantation followed by bortezomib and dexamethasone in Bence-Jones protein κ-type of multiple myeloma with systemic amyloidosis].
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Multiple Myeloma; Pyrazines; Transplantation, Autologous | 2015 |
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.
Topics: Amyloid; Amyloidosis; Boronic Acids; Bortezomib; Cooperative Behavior; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Europe; Heart Diseases; Humans; Kidney Diseases; Pyrazines; Treatment Outcome | 2015 |
Upfront CyBorD in AL amyloidosis.
Topics: Amyloidosis; Boronic Acids; Cyclophosphamide; Dexamethasone; Humans; Pyrazines | 2015 |
Blaming the Right Fluorescent in Situ Hybridization.
Topics: Amyloidosis; Boronic Acids; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Dexamethasone; Female; Humans; Male; Pyrazines; Translocation, Genetic | 2015 |
Reply to R. Warsame et al.
Topics: Amyloidosis; Boronic Acids; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Dexamethasone; Female; Humans; Male; Pyrazines; Translocation, Genetic | 2015 |
Analysis of diagnostic and therapeutic strategies in advanced cardiac light-chain amyloidosis.
Topics: Amyloidosis; Boronic Acids; Delayed Diagnosis; Humans; Pyrazines; Retrospective Studies | 2016 |
Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant.
Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Pyrazines; Recurrence; Transplantation, Autologous | 2010 |
An unusual case of transient dermatological reaction to bortezomib in AL amyloidosis.
Topics: Amyloidosis; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Paraproteinemias; Protease Inhibitors; Pyrazines | 2010 |
[IgM-lambda multiple myeloma presenting with systemic amyloidosis].
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Fatal Outcome; Humans; Immunoglobulin M; Male; Middle Aged; Multiple Myeloma; Paraproteinemias; Pyrazines; Vincristine | 2009 |
[The effects and safety of bortezomib combined with dexamethasone in the treatment of primary systemic amyloidosis].
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Drug Combinations; Female; Humans; Male; Middle Aged; Pyrazines; Treatment Outcome | 2009 |
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Acute dyspnea from treatment of AL amyloidisis with bortezomib.
Topics: Acute Disease; Aged; Amyloidosis; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Dyspnea; Humans; Kidney Diseases; Male; Middle Aged; Protease Inhibitors; Pyrazines | 2011 |
Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Pyrazines; Remission Induction; Retrospective Studies; Treatment Outcome | 2011 |
Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib.
Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Echocardiography; Heart Diseases; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Myocardium; Protease Inhibitors; Pyrazines; Stroke Volume; Treatment Outcome | 2010 |
De novo AL amyloidosis in the kidney allograft.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Kidney Transplantation; Male; Melphalan; Middle Aged; Prednisone; Proteinuria; Pyrazines; Remission Induction; Treatment Outcome | 2011 |
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.
Topics: Aged; Amyloidosis; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin M; Lymphatic Diseases; Male; Middle Aged; Pyrazines; Rituximab | 2011 |
Cervical amyloidoma successfully treated with bortezomib and dexamethasone.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cervical Vertebrae; Dexamethasone; Humans; Magnetic Resonance Imaging; Male; Pyrazines; Spinal Neoplasms | 2011 |
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
Topics: Adult; Aged; Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Immunosuppressive Agents; Lenalidomide; Male; Melphalan; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2012 |
A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia.
Topics: Amyloidosis; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Protease Inhibitors; Pyrazines | 2011 |
Heavy-chain amyloidosis in TGFBI-negative and gelsolin-negative atypical lattice corneal dystrophy.
Topics: Amyloid; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Corneal Dystrophies, Hereditary; Dexamethasone; DNA Mutational Analysis; Extracellular Matrix Proteins; Gelsolin; Glucocorticoids; Humans; Immunoglobulin Heavy Chains; Male; Mass Spectrometry; Melphalan; Microscopy, Confocal; Middle Aged; Mutation; Nephrotic Syndrome; Paraproteinemias; Pyrazines; Sequence Analysis, Protein; Transforming Growth Factor beta | 2011 |
Bortezomib in systemic AL amyloidosis: a single center experience.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Pyrazines | 2011 |
Bortezomib (Velcade) treatment of AL amyloidosis: Indiana University experience.
Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin Light Chains; Indiana; Male; Middle Aged; Pyrazines | 2011 |
Quick response to bortezomib plus dexamethasone in a patient with AL amyloidosis in first relapse.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Echocardiography; Female; Humans; Immunoglobulin Light Chains; Pyrazines; Recurrence | 2011 |
Cardiac amyloidosis: a treatable disease, often overlooked.
Topics: Adrenergic beta-Antagonists; Amyloidosis; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Boronic Acids; Bortezomib; Calcium Channel Blockers; Dexamethasone; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Humans; Lenalidomide; Melphalan; Middle Aged; Myocardium; Prealbumin; Pyrazines; Severity of Illness Index; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Amyloidosis.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Delayed Diagnosis; Dexamethasone; Dyspnea; Heart Diseases; Humans; Kidney; Kidney Diseases; Male; Narration; Pyrazines; Quality of Life; Serum Amyloid A Protein; Thalidomide | 2011 |
[Unusual skin alterations in a 72-year-old patient with multiple myeloma].
Topics: Aged; Amyloidosis; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Female; Humans; Multiple Myeloma; Pyrazines; Skin Diseases; Treatment Outcome | 2012 |
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.
Topics: Amyloid; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clonal Evolution; Cohort Studies; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome | 2012 |
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.
Topics: Amyloid; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Cytogenetic Analysis; Dexamethasone; Humans; Kidney; Pyrazines; Remission Induction; Retrospective Studies; Survival Analysis; Time Factors | 2012 |
Myeloma: diagnosis complications and supportive care.
Topics: Amyloidosis; Anemia; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pyrazines; Quality of Life; Renal Insufficiency; Thrombosis; Zoledronic Acid | 2012 |
[Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
Topics: Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Lenalidomide; Melphalan; Prednisone; Pyrazines; Thalidomide | 2012 |
Jejunal amyloidosis: a rare cause of severe gastrointestinal bleeding.
Topics: Aged, 80 and over; Amyloidosis; Antineoplastic Agents; Biopsy; Blood Transfusion; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Female; Gastrointestinal Hemorrhage; Glucocorticoids; Humans; Jejunal Diseases; Pyrazines | 2012 |
Cutaneous amyloid elastosis revealing multiple myeloma with systemic amyloidosis.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Diagnostic Errors; Elastic Tissue; Fatal Outcome; Female; Humans; Melphalan; Multiple Myeloma; Predictive Value of Tests; Pseudoxanthoma Elasticum; Pyrazines; Skin; Treatment Outcome | 2013 |
Erectile dysfunction associated with bortezomib treatment in a patient with multiple myeloma and amyloidosis.
Topics: Amyloidosis; Boronic Acids; Bortezomib; Erectile Dysfunction; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2013 |
Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis.
Topics: Adult; Aged; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Pyrazines; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2013 |
Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Melphalan; Myeloablative Agonists; Myocardium; Pyrazines; Steroids; Survival Analysis; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Bortezomib in the treatment of AL amyloidosis: targeted therapy?
Topics: Amyloidosis; Animals; Boronic Acids; Bortezomib; Humans; Kidney; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2007 |
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.
Topics: Amyloidosis; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Immunosuppressive Agents; Male; Protease Inhibitors; Pyrazines; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide | 2008 |